Buradasınız

Lupus psikozu tedavisinde intravenöz immünoglobulinlerin kullanımı: olgu sunumu

USE OF INTRAVENOUS IMMUNOGLOBULINS IN TREATMENT OF LUPUS PSYCHOSIS: A CASE REPORT

Journal Name:

Publication Year:

Abstract (2. Language): 
Systemic Lupus Erythematosus (SLE) is a multisystem autoimmune disease. Its manifestations are protean and virtually any organ system can be involved. The disease in children is generally more acute and more severe than that in adult. Recently it has been notified that intravenous immunoglobulins (IVIG) in patients with cerebral lupus have improved fairly. In this report, we present a case of systemic lupus erythematosus involving multiple organ systems, including psychosis which did not respond to high-dose intravenous corticosteroid therapy. Alter application of IVIG (400 mg/kg/24 hr, 5 day/month) as an adjunctive agent, psychosis of the patient was completely improved. This report supports the finding that IVIG therapy may successfully be used for nonresponders to conventional treatments of SLE, especially for those with cerebral complications.
Abstract (Original Language): 
Sistemik lupus eritematosus (SLE) otoimmun bir multisistem hastalığıdır. Belirtileri çok yönlüdür ve hemen her organı tutabilir. SLE genellikle çocuklarda erişkinlerden daha akut başlar ve ağır seyreder. Son zamanlarda serebral lupuslu hastalarda intravenöz immunglobülinlerh oldukça iyi sonuçlar verdiği bildirilmektedir. Bu makalede, psikoz ve birden fazla organ tutulumu olan; yüksek doz intravenöz kortikosteroide yani vermeyen, IVIG uygulamasını takiben (400 mg/kg/gün, 5 gün/ay) psikoz tablosu tamamen düzelen bir SLE olgusu sunuldu. Bu bulgu, IVIG'in SLE'nin konvansiyonel tedavisine yanıt vemeyen olgularda, özellikle de serebral lupus da başarılı bir şekilde kullanılabileceğin desteklemektedir.
278-280

REFERENCES

References: 

1. Lehman T3A. A Practical Guide to SLE. The Pedsatr Clin N Am 1995; 42:1223-8.
2. Fesler B3, Soumpas DT. Severe major organ involvement in systemic lupus erythematosus. Diagnosis and management. Rheum Dis Clm Am 1995; 21: 81-8.
3. Sibley 3T, Olszynski WP, Decoteau WE, Sundaram MB. The incidence and prognosis of central nervous system disease in systemic lupus erythematosus. 3 Rheumatol 1992; 19 : 47-52.
4. Tekin N, Kural N, Koçak AD, Köse S. Diabetes insipidus in a pediatric patient with systemic erythematosus. A case report. Turk j Pedatr 1997; 39: 281-4.
5. Franaoni C, Fioravanti A, Gelli R, et al. Long-term treatment with i.v. immunoglobulin in the therapy of systemic lupus erythematosus. Recent Prog Med 1993; 84 : 679-6.
6. Sany j. Intravenous immunoglobulin therapy for rheumatic deeases. Curr Opm Rhematol 1994; 6: 305-10.
7. Lepore L. Experimental treatment with high-dose gamma globulme in autoimmune diseases. Pediatr Med Chir 1993; 15: 337^10.
8. Becker BN, Fuchs H, Hakim R. IVIG in the treatment of patients with systemic lupus erythematosus and end-stage renal disease, j Am Soc Nephrol 1995; 5: 1746-50.
9. Horoshovski D, Amrtal H, Katz M, et al. Pseudotumor cerebri in SLE. Clm Rheumatol 1995; 14:708-10.
10. Tomer Y, Shoenfeld Y. Successful treatment of psychose secondary to SLE with high dose IVIG. Clin Exp Rheumatol 1992; 10: 391-3.
11. Nectoux F, Fuller ZL, Gosot C, et al. Lupus chorea revealing. Rev Rhum Hal Osteoartic 1992; 59: 436-8.
12. al Arfaj HF, Naddaf HO. Cerebellar atrophy in systemic lupus erythematosus. Lupus 1995; 4:412-4.
13. Lake DF, Landsperger W3, Bernstein RM et al. Characterization of autoantibodies directed against T cell receptors. Adv Exp Med Biol 1995; 383: 223-9.
14. Goldfien A. Adrenocorticosteroids & Adrenocortical Antagonists. In: Katzung BG (ed). Base St Clinical Pharmacology. California: Appleton &LangeCo, 1992:546.

Thank you for copying data from http://www.arastirmax.com